Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT06904482
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndromes
  • aGVHD

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Haplo-Identical / Cord Blood Transplant — BIOLOGICAL
    Cord Blood Unit Selection Cord Blood Unit Selection should be consistent with published guidelines5 with the understanding that the goal cell dose is 1x105 CD34 cells/kg in this protocol. ABO matching and donor specific antibodies should be taken into account in the selection of the CB unit. Haplo-Donor Selection Haplo-identical siblings and younger male donors are preferred. ABO matching, CMV compatibility, and donor specific antibodies should be taken into account in the selection of the donor.

Study Details

The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.

Key Dates

Start date
Aug 13, 2025
Status verified
Feb 2026
Primary completion
Feb 24, 2027
Completion
Feb 25, 2030

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Haplo-Identical / Cord Blood Transplant

Primary Outcome Measure

Progression free survival(PFS) at 6 months after transplant [ Time Frame: 6 months after transplant ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer CenterClevelandOhio44106
Leland Metheny, MD

Find similar trials in Cleveland, OH

By research site
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center· Cleveland, OH

Related Studies